NuCana Plc, a clinical stage biopharmaceutical company, leverages its ProTide technology to enhance cancer treatment, with key drugs like NUC-3373 and NUC-7738 currently in clinical trials. NUC-3373 targets advanced colorectal cancer, while NUC-7738, a transformation of 3’-deoxyadenosine, is being tested in patients with advanced solid tumors.
NuCana plc (NCNA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, NuCana plc's actual EPS was -$3.00, missing the estimate of -$1.85 per share, resulting in a -62.57% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
